VF
PMCB icon

Virtu Financial’s PharmaCyte Biotech PMCB Stock Holding History

Virtu Financial’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25K Buy
+37,532
New +$28.7K ﹤0.01% 1368

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Virtu Financial's PMCB Position: Q1 2026 in Review

Virtu Financial opened a new position in PharmaCyte Biotech (PMCB) in Q1 2026: 37,532 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #1368 among its holdings.

32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Virtu Financial held 37,532 shares of PharmaCyte Biotech worth $25K as of Q1 2026.
  • PharmaCyte Biotech was a new Virtu Financial position in Q1 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1368 holding.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.